Tag: aureus
PHAXIAM Therapeutics announces the recruitment of the first patient in the phase 1 study in infective endocarditis caused by Staphylococcus aureus – 04/15/2024 at 07:30
The study plans the inclusion of 12 patients in 5 French clinical centers The first results are expected in the 3rd quarter of 2024 This study makes it possible to…
PHAXIAM Therapeutics announces the recruitment of the first patient in the phase 1 study in infective endocarditis caused by Staphylococcus aureus – 04/15/2024 at 07:30
The study plans the inclusion of 12 patients in 5 French clinical centers The first results are expected on 3 th quarter 2024 This study makes it possible to evaluate…
2023 – PHAXIAM Therapeutics obtains the necessary authorizations to launch its phase 1 study in infectious endocarditis caused by Staphylococcus aureus
Approval of the study protocol by the ANSM and the Committee for the Protection of People (CPP) Sud-Est II Lyon Start of recruitment of 12 patients planned during the 4th…
PHAXIAM Therapeutics obtains the necessary authorizations to launch its phase 1 study in infective endocarditis caused by Staphylococcus aureus – 10/24/2023 at 10:05 p.m.
Approval of the study protocol by the ANSM and the Committee for the Protection of People (CPP) Sud-Est II Lyon Start of recruitment of 12 patients planned during the 4th…
PHAXIAM Therapeutics obtains the necessary authorizations to launch its phase 1 study in infective endocarditis caused by Staphylococcus aureus – 10/24/2023 at 10:05 p.m.
Approval of the study protocol by the ANSM and the Committee for the Protection of People (CPP) Sud-Est II Lyon Start of recruitment of 12 patients planned for the 4th…
PHAXIAM Therapeutics announces a high level of performance of its two anti-Staphylococcus aureus phages on clinical strains – 10/09/2023 at 10:05 p.m.
Data obtained from the phagogram developed by PHAXIAM, the first phage sensitivity test with CE marking, showed a response rate of 98% on 105 clinical strains of S. aureus. Lyon…
PHAXIAM Therapeutics announces a high level of performance of its two anti-Staphylococcus aureus phages on clinical strains – 10/09/2023 at 10:05 p.m.
PHAXIAM Therapeutics announces a high level of performance of its two anti- Staphylococcus aureus on clinical strains Data obtained from the phagogram developed by PHAXIAM, the first phage sensitivity test…
Pherecydes Pharma has submitted an application for authorization of a phase I clinical study in infective endocarditis caused by Staphylococcus aureus
By Hector Chaunu Published on 06/08/2023 at 07:35 Photo credit © ChaunuPictures (Boursier.com) — Pherecydes Pharmaa biotechnology company…
Pherecydes Pharma announces the positive recommendation of the DSMB for the continuation of its phase II clinical study PhagoDAIR in osteoarticular infections on prostheses caused by Staphylococcus aureus – 2022-11-29 at 18:00
Nantes, November 29, 2022 – 6 p.m. CET – Pherecydes Pharma (FR0011651694 – ALPHE, PEA-PME eligible), a biotechnology company specializing in precision phage therapy intended to treat antibiotic-resistant and/or complicated…
Pherecydes: AAC for anti-S phages. aureus – 05/31/2022 at 13:43
(CercleFinance.com) – Pherecydes Pharma announces that it has obtained, for its anti-Staphylococcus aureus (S. aureus) phages, a Compassionate Access Authorization (AAC) from the ANSM, which will allow the company to…
Pherecydes Pharma obtains Compassionate Access Authorization (AAC) from the ANSM for its anti-Staphylococcus aureus phages – 05/30/2022 at 18:00
Frédérique Vieville, Quality Director of Pherecydes Pharma, comments: “We are proud to be one of the very first French companies to obtain compassionate access authorization, associated with a Temporary Use…
Staphylococcus aureus: transmission, symptoms, treatments, risks: Femme Actuelle Le MAG
Staphylococcus aureus: transmission, symptoms, treatments, risks: Femme Actuelle Le MAG Path 2 645DBCB3-7979-441A-BA4B-98E7BF17E1BE 1785B508-2A96-4CF5-AA87-79B0FE0441BF advertising source site-44